M. Block

Is bortezomib, a proteasome inhibitor, effective in treating cancer-associated weight loss? Preliminary results from the North Central Cancer Treatment Group

N. Foster, J. Kugler, S. Alberts, 2005, Supportive Care in Cancer.

A Phase II Study of Topical Ceramides for Cutaneous Breast Cancer

J. Sloan, C. Loprinzi, S. Alberts, 2003, Breast Cancer Research and Treatment.

Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131

W. Symmans, A. Wolff, A. DeMichele, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radiation carcinogenesis in man: New primary neoplasms in fields of prior therapeutic radiation

H. Southwick, A. Sadove, A. Doolas, 1981, Cancer.

Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients

Minetta C. Liu, A. DeMichele, M. Regan, 2021, NPJ breast cancer.

Abstract P1-01-01: Circulating tumor cell number and CTC-endocrine therapy index predict clinical outcomes in ER positive metastatic breast cancer patients: Results of the COMETI Phase 2 trial

A. DeMichele, M. Regan, P. Marcom, 2017 .

Metastatic neuroblastoma arising in an ovarian teratoma with long‐term survival. Case report and review of the literature

C. Davis, Enid Gilbert, M. Block, 1984, Cancer.

Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial).

G. Curigliano, A. Brenner, D. Cameron, 2021, European journal of cancer.

Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: a North Central Cancer Treatment Group study.

D. Sargent, J. Kugler, P. Burch, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Efficacy and Safety of Weekly Paclitaxel With or Without Oral Alisertib in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.

M. Danso, J. O’Shaughnessy, Ling Ma, 2021, JAMA network open.

Abstract PD13-04: Impact of tucatinib on health-related quality of life in patients with HER2+ metastatic breast cancer with stable and active brain metastases

K. Gelmon, G. Curigliano, D. Cameron, 2021 .